SCHEMBL12295264

SCHEMBL12295264

CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(-c2ccccc2C(F)(F)F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 8/20 0.61
CYP2C19 P33261 6/20 0.61
CYP3A4 P08684 3/20 0.61
LMNA P02545 1/20 0.48
CYP1A2 P05177 1/20 0.43
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
EPHX2 P34913 1/20 0.41
SLC2A1 P11166 1/20 0.41
USP1 O94782 1/20 0.41
WDR48 Q8TAF3 1/20 0.41
CLK1 P49759 1/20 0.40
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17580468 0.91 CYP2C9 (0.51) CYP2C9CYP2C19CYP3A4LMNACYP1A2
SCHEMBL12295283 0.91 CYP2C9 (0.61) CYP2C9CYP2C19CYP3A4LMNACYP1A2
SCHEMBL13837948 0.90 CYP2C9 (0.48) CYP2C9CYP2C19CYP3A4LMNAALDH1A1
SCHEMBL12295472 0.88 CYP2C9 (0.63) CYP2C9CYP2C19CYP3A4LMNACYP1A2
SCHEMBL2428194 0.87 CYP2C9 (0.62) CYP2C9CYP2C19CYP3A4LMNACYP1A2
SCHEMBL13837986 0.87 CYP2C9 (0.61) CYP2C9CYP2C19CYP3A4LMNAALDH1A1
SCHEMBL12294578 0.86 CYP2C9 (0.67) CYP2C9CYP2C19CYP3A4CYP1A2ALDH1A1
SCHEMBL2400683 0.85 CYP2C9 (0.69) CYP2C9CYP2C19CYP3A4LMNACYP1A2
SCHEMBL12295273 0.85 CYP2C9 (0.59) CYP2C9CYP2C19CYP3A4CYP1A2ALDH1A1
SCHEMBL2426016 0.85 CYP2C9 (0.71) CYP2C9CYP2C19CYP3A4LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9029389-B2 Anti-inflammation compounds INSTITUT PASTEUR KOREA (KR) 2015-05-12 US claimed
US-8865734-B2 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2014-10-21 US claimed
EP-2547678-B1 ANTI-INFECTIVE COMPOUNDS PASTEUR INSTITUT KOREA (KR) 2016-03-16 EP disclosed
US-9029389-B2 Anti-inflammation compounds INSTITUT PASTEUR KOREA (KR) 2015-05-12 US disclosed
US-9029389-B2 Anti-inflammation compounds INSTITUT PASTEUR KOREA (KR) 2015-05-12 US disclosed
US-8865734-B2 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2014-10-21 US disclosed
US-8865734-B2 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2014-10-21 US disclosed
US-20140155387-A1 Anti-Inflammation Compounds QURIENT, CO. LTD. (KR) 2014-06-05 US disclosed
US-20140155387-A1 Anti-Inflammation Compounds QURIENT, CO. LTD. (KR) 2014-06-05 US disclosed
US-20130065884-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2013-03-14 US disclosed
US-20130065884-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2013-03-14 US disclosed
WO-2011113606-A1 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065884-A1 Anti-Infective Compounds RABGGTB, ELANE, SERPINB1 CYP2C9 4235/4885CYP2C19 4181/4885CYP3A4 2915/4885
US-20140155387-A1 Anti-Inflammation Compounds NR0B1, NR0B2, NR5A2 CYP2C9 1210/4885CYP2C19 2085/4885CYP3A4 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.